STUDY OF THE EFFECT OF SOFOSBUVIR BASED THERAPY ON ESTIMATED GLOMERULAR FILTRATION RATE IN EGYPTIAN CHRONIC HEPATITIS C PATIENTS

Elsaied Ibrahim, Mohamed A. Elbealy, A. Nassar, H. Mostafa
{"title":"STUDY OF THE EFFECT OF SOFOSBUVIR BASED THERAPY ON ESTIMATED GLOMERULAR FILTRATION RATE IN EGYPTIAN CHRONIC HEPATITIS C PATIENTS","authors":"Elsaied Ibrahim, Mohamed A. Elbealy, A. Nassar, H. Mostafa","doi":"10.21608/jmalexu.2021.244166","DOIUrl":null,"url":null,"abstract":"Hepatitis C viral infection is endemic in Egypt with the highest prevalence rate of HCV Ab in the world (14.7%). [1] Direct-acting antiviral agents (DAAs) are molecules that target specific nonstructural proteins of virus C and result in disruption of viral replication and infection. [2] There are four classes of DAAs, which are defined by their mechanism of action and therapeutic target. They are; non-structural proteins NS 3/4A protease inhibitors (Simiprevir, paritaprevir), NS5B nucleoside polymerase inhibitors (Sofosbuvir), NS5B non-nucleoside polymerase inhibitors (Dasabuvir), and NS5A inhibitors (Daclatasvir). [3] National protocol of HCV treatment used in Egyptian patients infected with HCV (genotype 4) is a combination of daily sofosbuvir and any other DAAs. Compared to previously used treatments, sofosbuvir-based regimens provide a higher cure rate (>90%), fewer side effects, and a twoto fourfold reduction in duration of therapy.[4, 5]It allows most people to be treated successfully without the use of peglated interferon.[6,7]. Sofosbuvir is only administered orally. The peak concentration after oral administration is 0.5–2 hours post-dose, regardless of initial dose.[8&9] It is a prodrug. It is metabolized to the active metabolite antiviral agent GS-461203 (2'-deoxy-2'α-fluoro-β-C-methyluridine-5'triphosphate) in the liver. GS-461203 serves as a defective substrate for the NS5B protein, which is the viral RNA polymerase, thus acts as an inhibitor of viral RNA synthesis.[10] It appears to have a high barrier to develop resistance .Following a single 400mg oral dose of sofosbuvir 80٪ is excreted in urine; 14٪ is excreted in faeces, and 2.5٪ in expired air.[11] Sofosbuvir in patients with HCV infection and mild to moderate renal impairment (eGFR ≥30 ml/ min/1.73 m2) should be given according to the general recommendations. No dose Journal of the Medical Research Institute","PeriodicalId":440681,"journal":{"name":"Journal of the Medical Research Institute","volume":"97 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Medical Research Institute","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21608/jmalexu.2021.244166","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Hepatitis C viral infection is endemic in Egypt with the highest prevalence rate of HCV Ab in the world (14.7%). [1] Direct-acting antiviral agents (DAAs) are molecules that target specific nonstructural proteins of virus C and result in disruption of viral replication and infection. [2] There are four classes of DAAs, which are defined by their mechanism of action and therapeutic target. They are; non-structural proteins NS 3/4A protease inhibitors (Simiprevir, paritaprevir), NS5B nucleoside polymerase inhibitors (Sofosbuvir), NS5B non-nucleoside polymerase inhibitors (Dasabuvir), and NS5A inhibitors (Daclatasvir). [3] National protocol of HCV treatment used in Egyptian patients infected with HCV (genotype 4) is a combination of daily sofosbuvir and any other DAAs. Compared to previously used treatments, sofosbuvir-based regimens provide a higher cure rate (>90%), fewer side effects, and a twoto fourfold reduction in duration of therapy.[4, 5]It allows most people to be treated successfully without the use of peglated interferon.[6,7]. Sofosbuvir is only administered orally. The peak concentration after oral administration is 0.5–2 hours post-dose, regardless of initial dose.[8&9] It is a prodrug. It is metabolized to the active metabolite antiviral agent GS-461203 (2'-deoxy-2'α-fluoro-β-C-methyluridine-5'triphosphate) in the liver. GS-461203 serves as a defective substrate for the NS5B protein, which is the viral RNA polymerase, thus acts as an inhibitor of viral RNA synthesis.[10] It appears to have a high barrier to develop resistance .Following a single 400mg oral dose of sofosbuvir 80٪ is excreted in urine; 14٪ is excreted in faeces, and 2.5٪ in expired air.[11] Sofosbuvir in patients with HCV infection and mild to moderate renal impairment (eGFR ≥30 ml/ min/1.73 m2) should be given according to the general recommendations. No dose Journal of the Medical Research Institute
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
索非布韦为基础的治疗对埃及慢性丙型肝炎患者肾小球滤过率的影响研究
丙型肝炎病毒感染是埃及的地方病,其丙型肝炎病毒的流行率是世界上最高的(14.7%)。[1]直接作用抗病毒药物(Direct-acting antiviral agents, DAAs)是一种以病毒C的特异性非结构蛋白为靶点,破坏病毒复制和感染的分子。[2] daa可分为四类,根据其作用机制和治疗靶点来定义。他们是;非结构蛋白ns3 / 4a蛋白酶抑制剂(Simiprevir, paritaprevir), NS5B核苷聚合酶抑制剂(Sofosbuvir), NS5B非核苷聚合酶抑制剂(Dasabuvir)和NS5A抑制剂(Daclatasvir)。[3]埃及HCV(基因型4)感染患者的国家HCV治疗方案是每日索非布韦和任何其他daa的组合。与以前使用的治疗方法相比,以索非布韦为基础的方案提供更高的治愈率(>90%),更少的副作用,并且治疗时间缩短了2到4倍。[4,5]它允许大多数人在不使用聚乙二醇干扰素的情况下成功治疗[6,7]。索非布韦只能口服。无论初始剂量如何,口服给药后的浓度峰值在给药后0.5-2小时。[8&9]它是一种前药。在肝脏代谢为活性代谢物抗病毒药物GS-461203(2′-脱氧-2′α-氟-β- c -甲基尿嘧啶-5′三磷酸)。GS-461203作为病毒RNA聚合酶NS5B蛋白的缺陷底物,因此作为病毒RNA合成的抑制剂。[10]它似乎具有产生耐药性的高屏障。单次口服400mg索非布韦后,80从尿液中排出;14.4 在粪便中排泄,2.5 在空气中排泄。[11]对于HCV感染和轻中度肾功能损害(eGFR≥30 ml/ min/1.73 m2)的患者,应按照一般建议给予索非布韦。无剂量医学研究所杂志
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Ketogenic diet and beta-hydroxybutyrate modulate the hepatic expression of AKT/PI3K/mTOR pathway during treatment of obesity in rats. PD-1/PD-L1 AXIS INHIBITORS AS PROMISING STRATEGY FOR MANAGEMENT OF HEPATOCELLULAR CARCINOMA: EXPECTATIONS, BOUNDARIES AND PITFALLS VALUE OF SERUM INTERLEUKIN-22 IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND ITS RELATION TO DISEASE CHARACTERISTICS ARGON PLASMA COAGULATION VERSUS BAND LIGATION IN GASTRIC ANTRAL VASCULAR ECTASIA IN CHRONIC HCV-RELATED LIVER CIRRHOSIS EFFECTIVE TREATMENT OF MENINGITIS CAUSED BY MULTIPLE ORGANISMS INCLUDING MDR E. COLI, MDR KLEBSIELLA PNEUMONIAE AND MRSA: A CASE REPORT
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1